Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBT: 2015-2025

Historic EBT for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$11.2 million.

  • Spyre Therapeutics' EBT rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.66%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.62% up from last year.
  • Spyre Therapeutics' EBT amounted to -$11.2 million in Q3 2025, which was up 69.54% from -$36.7 million recorded in Q2 2025.
  • Spyre Therapeutics' EBT's 5-year high stood at -$11.2 million during Q3 2025, with a 5-year trough of -$217.1 million in Q2 2023.
  • In the last 3 years, Spyre Therapeutics' EBT had a median value of -$43.8 million in 2024 and averaged -$58.1 million.
  • In the last 5 years, Spyre Therapeutics' EBT plummeted by 872.82% in 2023 and then skyrocketed by 83.80% in 2025.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' EBT stood at -$20.4 million in 2021, then climbed by 8.03% to -$18.8 million in 2022, then tumbled by 236.35% to -$63.2 million in 2023, then grew by 10.90% to -$56.3 million in 2024, then soared by 83.80% to -$11.2 million in 2025.
  • Its EBT stands at -$11.2 million for Q3 2025, versus -$36.7 million for Q2 2025 and -$44.8 million for Q1 2025.